Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report Abstract #1390

Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Aim(s): To report the diagnosis and treatment of a case with ectopic malignant insulinoma.
Materials and methods: A 31-year-old woman was detected a lesion(size 1.7cm) in the liver by ultrasound in 2008(misdiagnosed as hemangioma). Since 2012 she complained of confusion, hand trembling, palpitation and sweating, and these symptoms occurred more frequently over the time. On May 2014 she was found to be hypoglycemic, elevated serum insulin and C-P, Abdomen CT with contrast showed multiple lesions in liver(largest 4.3cm), enlarged lymph nodes around the pancreas, a lesion(3.5cm) at proximal jejunum. Liver biopsy showed NET G1, Ki-67(+2%). Octreoscan showed high expression of SSR in jejunum area, multiple liver masses and mesenteric lymph nodes. 68Ga-exendin-4 PET/CT confirmed the lesion located at jejunum section, below the body of pancreas, where expressed GLP-1R was most hypercaptant(SUV 21.7), supposed to jejunum origin. The diagnosis of ectopic malignant insulinoma was made.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: Ferrero A, Bellini E, Brizzi M P, Pia A, ...
#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Maria Vittoria Davì
#1101 Malignant Insulinoma in a Patient with Diabetes: Response to Treatment and a Return to Insulin Injections
Introduction: A 64 year old male with a fourteen year history of diabetes had been treated with insulin for eight years. Over a four week period he noticed that his insulin requirements were reducing and he experienced episodes of symptomatic hypoglycaemia and upper abdominal pain. Following referral a CT scan was performed which revealed numerous liver metastases and a 8.4 by 5.2 cm mass replacing the pancreas. Liver biopsy diagnosed a neuroendocrine tumour with a MIB-1 index of up to 18%. The tumour was somatostatin receptor positive as evidenced by an octreotide scan.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr David Sherriff
Authors: Sherriff D, Drake B, ...
Keywords: insulinoma, diabetes, prrt
#2124 A Case Report of a Malignant Insulinoma
Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Theodoros Tegos
Keywords: malignant, insulinoma
#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Maria Vittoria Davì